TCTischa J. M. van der Cammen

Tischa J. M. van der Cammen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tischa J. M. van der Cammen has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Nathalie van der Velde

    Department of Internal Medicine, Section of Geriatric Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands

    15 shared publications
  • Ed F. van Beeck

    Public Health Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

    10 shared publications
  • Peter Patka

    Department of Emergency Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    7 shared publications
  • Carolyn Shanty Sterke

    Research Centre Innovations in Care, Rotterdam University of Applied Sciences, Rotterdam, The Netherlands

    5 shared publications
  • Caspar W. N. Looman

    Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands

    5 shared publications
  • Klaas A. Hartholt

    Section of Geriatric Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    5 shared publications

Latest Publications

  • Open Access

    Cost-utility of medication withdrawal in older fallers: results from the improving medication prescribing to reduce risk of FALLs (IMPROveFALL) trial

    by the IMPROveFALL trial collaborators, Suzanne Polinder, Nicole D. A. Boyé, Francesco U. S. Mattace-Raso, Nathalie Van der Velde, Klaas A. Hartholt, Oscar J. De Vries, Paul Lips, Tischa J. M. Van der Cammen, Peter Patka, et al.

    The use of Fall-Risk-Increasing-Drugs (FRIDs) has been associated with increased risk of falls and associated injuries. This study investigates the effect of withdrawal of FRIDs versus ‘care as usual’ on health-related quality of life (HRQoL), costs, and cost-utility in community-dwelling older fallers. In a prospective multicenter randomized controlled trial FRIDs assessment combined with FRIDs-withdrawal or modification was compared with ‘care as usual’ in older persons, who visited the emergency department after experiencing a fall. For the calculation of costs the direct medical costs (intramural and extramural) and indirect costs (travel costs) were collected for a 12 month period. HRQoL was measured at baseline and at 12 months follow-up using the EuroQol-5D and Short Form-12 version 2. The change in EuroQol-5D and Short Form-12 scores over 12 months follow-up within the control and intervention groups was compared using the Wilcoxon Signed Rank test for continuous variables and the McNemar test for dichotomous variables. The change in scores between the control and intervention groups were compared using a two-way analysis of variance. We included 612 older persons who visited an emergency department because of a fall. The mean cost of the FRIDs intervention was €120 per patient. The total fall-related healthcare costs (without the intervention costs) did not differ significantly between the intervention group and the control group (€2204 versus €2285). However, the withdrawal of FRIDs reduced medication costs with a mean of €38 per participant. Furthermore, the control group had a greater decline in EuroQol-5D utility score during the 12-months follow-up than the intervention group (p = 0.02). The change in the Short Form-12 Physical Component Summary and Mental Component Summary scores did not differ significantly between the two groups. Withdrawal of FRID’s in older persons who visited an emergency department due to a fall, did not lead to reduction of total health-care costs. However, the withdrawal of FRIDs reduced medication costs with a mean of €38 per participant in combination with less decline in HRQoL is an important result. The trial is registered in the Netherlands Trial Register ( NTR1593 – October 1st 2008).


  • Open Access

    Effectiveness of medication withdrawal in older fallers: results from the Improving Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) trial

    by Nicole D A Boyé, Nathalie Van Der Velde, Oscar J De Vries, Esther M M Van Lieshout, Klaas A Hartholt, Francesco U S Mattace-Raso, Paul Lips, Peter Patka, Ed F Van Beeck, Tischa J M Van Der Cammen, et al.

    To investigate the effect of withdrawal of fall-risk-increasing-drugs (FRIDs) versus ‘care as usual’ on reducing falls in community-dwelling older fallers. randomised multicentre trial. six hundred and twelve older adults who visited an Emergency Department (ED) because of a fall. withdrawal of FRIDs. primary outcome was time to the first self-reported fall. Secondary outcomes were time to the second self-reported fall and to falls requiring a general practitioner (GP)-consultation or ED-visit. Intention-to-treat (primary) and a per-protocol (secondary) analysis were conducted. The hazard ratios (HRs) for time-to-fall were calculated using a Cox-regression model. Differences in cumulative incidence of falls were analysed using Poisson regression. during 12 months follow-up, 91 (34%) control and 115 (37%) intervention participants experienced a fall; 35% of all attempted interventions were unsuccessful, either due to recurrence of the initial indication for prescribing, additional medication for newly diagnosed conditions or non-compliance. Compared to baseline, the overall percentage of users of ≥3 FRIDs at 12 months did not change in either the intervention or the control group. Our intervention did not have a significant effect on time to first fall (HR 1.17; 95% confidence interval 0.89–1.54), time to second fall (1.19; 0.78–1.82), time to first fall-related GP-consultation (0.66; 0.42–1.06) or time to first fall-related ED-visit (0.85; 0.43–1.68). in this population of complex multimorbid patients visiting an ED because of a fall, our single intervention of FRIDs-withdrawal was not effective in reducing falls. Netherlands Trial Register NTR1593.


  • Open Access

    Potential Influence of Aspirin on Neopterin and Tryptophan Levels in Patients with a Delirium

    by Angelique Egberts, Durk Fekkes, Gijsbertus Ziere, Tischa J. M. Van der Cammen, Francesco U. S. Mattace-Raso

    In an in vitro study, it was found that aspirin might decrease neopterin production and tryptophan degradation. The aim of the present study was to evaluate the possible association between aspirin use and mean neopterin and tryptophan levels in patients with and without a delirium and whether the use of aspirin is associated with a decreased prevalence of delirium. Neopterin and tryptophan levels were determined previously in acutely ill admitted patients aged ≥65 years. The possible influence of aspirin on mean levels of neopterin and tryptophan was investigated with univariate analysis of variance in adjusted models. Eighty-three patients were included; 22 had a delirium. In patients without a delirium (no aspirin (n = 31) versus aspirin (n = 27)), mean neopterin levels were 47.0 nmol/L versus 43.6 nmol/L (p = 0.645) and tryptophan levels were 33.1 µmol/L versus 33.9 µmol/L (p = 0.816). In patients with a delirium (no aspirin (n = 13) versus aspirin (n = 9)), mean neopterin levels were 77.8 nmol/L versus 71.1 nmol/L (p = 0.779) and tryptophan levels were 22.4 µmol/L versus 27.3 µmol/L (p = 0.439). No difference was found in the distribution of aspirin users between patients with and without a delirium. In this study, we found that the use of aspirin had no significant effect on mean levels of neopterin and tryptophan. However, the raw data suggest that there might be a potential influence in patients with a delirium. Aspirin use was not associated with a decreased prevalence of delirium.


  • Physical performance and quality of life in single and recurrent fallers: Data from the Improving Medication Prescribing to Reduce Risk of Falls study

    by Nicole DA Boyé, Francesco Us Mattace‐Raso, Esther Mm Van Lieshout, Klaas A Hartholt, Ed F Van Beeck, Tischa Jm Van der Cammen

    Aim: Although guidelines regarding falls prevention make a clear distinction between single and recurrent fallers, differences in functional status, physical performance, and quality of life in single and recurrent fallers have not been thoroughly investigated. Therefore, we investigated the differences in functional status, physical performance and health‐related quality of life (HRQoL) between single and recurrent fallers.Methods: From October 2008 to October 2011, 616 community‐dwelling older adults who visited the emergency department as a result of a fall were enrolled. Physical performance was assessed with the Timed Up & Go (TUG) test, the Five Times Sit to Stand (FTSS) test, handgrip strength and the tandem stand test. Functional status was measured using the activities of daily living and instrumental activities of daily living scales. HRQoL was measured using the European Quality of Life five dimensions (EQ‐5D), and the Short Form‐12 version 2. A general linear model was used to compare the means of the scores.Results: Recurrent falls in community‐dwelling older adults were associated with poorer physical performance as measured by the TUG test (P < 0.001), FTSS test (P = 0.011), handgrip strength (P < 0.001) and tandem stand (P < 0.001), and lower HRQoL scores as measured by the EQ‐5D (P = 0.006) and SF‐12 (P = 0.006 and P = 0.012).Conclusion: The present findings provide further evidence that recurrent fallers have poorer physical performance and quality of life than single fallers. Recurrent falls might be a symptom of underlying disease and frailty, and reason for further assessment. Geriatr Gerontol Int 2015; 15: 350–355.


  • Open Access

    Drug cessation in complex older adults: time for action

    by Tischa Jm van der Cammen, Chakravarthi Rajkumar, Graziano Onder, Carolyn S Sterke, Mirko Petrovic

    Background: general opinion is growing that drug cessation in complex older patients is warranted in certain situations. From a clinical viewpoint, drug cessation seems most warranted in four situations, i.e., falls, delirium, cognitive impairment and end-of-life situations. To date, little information about the effects of drug cessation in these four situations is available. Objectives: to identify the effects and effectiveness of drug cessation on falls, delirium and cognitive impairment. For end-of-life situations, we reviewed cessation of inappropriate drug use. Methods: electronic databases were searched using MeSH terms and relevant keywords. Studies published in English were included if they evaluated the effects of drug cessation in older persons, aged ≥65 years, with falls, delirium or cognitive impairment; or cessation of inappropriate drug use in end-of-life situations. Results: we selected seven articles for falls, none for delirium, two for cognition and two for end-of-life situations. Withdrawal of psychotropics reduced fall rate; a prescribing modification programme for primary care physicians reduced fall risk. Withdrawal of psychotropics and a systematic reduction of polypharmacy resulted in an improvement of cognition. Very little rigorous research has been conducted on reducing inappropriate medications in patients approaching end of life. Conclusion: little research has focussed on drug cessation. Available studies showed a beneficial impact of cessation of psychotropic drugs on falls and cognitive status. More research in this field is needed. The issue of systematic drug withdrawal in end-of-life cases is controversial, but is increasingly relevant in the face of rising numbers of older people of this clinical status.


  • Vitamin D and Physical Performance in Older Men and Women Visiting the Emergency Department Because of a Fall: Data from the Improving Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) Study

    by Nicole D. A. Boyé, Christian Oudshoorn, Nathalie van der Velde, Esther M. M. van Lieshout, Oscar J. de Vries, Paul Lips, Ed F. van Beeck, Peter Patka, Tischa J. M. van der Cammen

    Objectives: To investigate whether serum 25‐hydroxy vitamin D (25( OH ) D ) is associated with physical performance in men and women. Design: Cross‐sectional. Setting: Emergency departments ( ED s) of five hospitals. Participants: Older adults who visited an ED because of a fall (N = 616). Measurements: Physical performance was assessed using the T imed U p and G o T est, the F ive T ime S it to S tand T est, handgrip strength, and the tandem stand test. Multivariate linear regression was used to assess the association between physical performance and log‐transformed 25( OH ) D concentration adjusted for potential confounders. Results: In men, higher serum 25( OH ) D concentration was significantly associated with better handgrip strength (regression coefficient ( B ) = 3.86, 95% confidence interval ( CI ) = 2.04−5.69), faster TUG time ( B = −2.82, 95% CI = −4.91 to −0.73), and faster FTSS time ( B = −3.39, 95% CI = −5.67 to −1.11). In women, higher serum 25( OH ) D concentration was significantly associated with faster TUG time ( B = −2.68, 95% CI = −4.87 to −0.49). Conclusion: A positive association was found between serum 25( OH ) D level and physical performance in men and women. Intervention studies are needed of vitamin D –deficient older men and women to further investigate the effect of vitamin D supplementation in this group.


  • New Insights: Dose‐Response Relationship Between Psychotropic Drugs and Falls: A Study in Nursing Home Residents With Dementia

    by Carolyn S. Sterke, Ed F. van Beeck, Nathalie van der Velde, Gijsbertus Ziere, Mirko Petrovic, Caspar W. N. Looman, Tischa J. M. van der Cammen

    The contribution of specific psychotropic drugs to fall risk in patients with dementia has not been quantified precisely until now. The authors evaluated the dose‐response relationship between psychotropic drugs and falls in nursing home residents with dementia. Daily drug use and daily falls were recorded in 248 nursing home residents with dementia from January 1, 2006, to January 1, 2008. For each day of the study period, data on drug use were abstracted from the prescription database, and falls were retrieved from a standardized incident report system, resulting in a data set of 85 074 person‐days. The authors found significant dose‐response relationships for the use of antipsychotics (hazard ratio [HR], 2.78; 95% confidence interval [CI], 1.49–5.17), anxiolytics (1.60; 1.20–2.14), hypnotics and sedatives (2.58; 1.42–4.68), and antidepressants (2.84; 1.93–4.16). Fall risk increased significantly with 28% at 0.25 of the defined daily dose (DDD) of an antipsychotic or antidepressant, with 8% at 0.2 of the DDD of an anxiolytic, and with 56% at 0.5 of the DDD of a hypnotic or sedative; it increased further with dose increments and with combinations of psychotropics. Even at low dosages, psychotropic drugs are associated with increased fall risk in nursing home residents with dementia.


  • End of the Spectacular Decrease in Fall-Related Mortality Rate: Men Are Catching Up

    by Klaas A. Hartholt, Suzanne Polinder, Ed F. van Beeck, Nathalie van der Velde, Esther M. M. van Lieshout, Peter Patka, Tischa J. M. van der Cammen

    Objectives. We determined time trends in numbers and rates of fall-related mortality in an aging population, for men and women. Methods. We performed secular trend analysis of fall-related deaths in the older Dutch population (persons aged 65 years or older) from 1969 to 2008, using the national Official-Cause-of-Death-Statistics. Results. Between 1969 and 2008, the age-adjusted fall-related mortality rate decreased from 202.1 to 66.7 per 100 000 older persons (decrease of 67%). However, the annual percentage change (change per year) in mortality rates was not constant, and could be divided into 3 phases: (1) a rapid decrease until the mid-1980s (men −4.1%; 95% confidence interval [CI] = −4.9, −3.2; women −6.5%; 95% CI, −7.1, −5.9), (2) flattening of the decrease until the mid-1990s (men −1.4%; 95% CI = −2.4, −0.4; women −2.0%; 95% CI = −3.4, −0.6), and (3) stable mortality rates for women (0.0%; 95% CI = −1.2, 1.3) and rising rates for men (1.9%; 95% CI = 0.6, 3.2) over the last decade. Conclusions. The spectacular decrease in fall-related mortality ended in the mid-1990s and is currently increasing in older men at similar rates to those seen in women. Because of the aging society, absolute numbers in fall-related deaths are increasing rapidly.


  • Why older people refuse to participate in falls prevention trials: A qualitative study

    by Annemijn B.M. Elskamp, Klaas A. Hartholt, Peter Patka, Ed F. van Beeck, Tischa J.M. van der Cammen